Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Molecular differences with therapeutic implications in early-onset compared to average-onset cholangiocarcinoma.
Authors
Thejus Jayakrishnan
Taussig Cancer Institute, Cleveland, OH
Thejus Jayakrishnan , Yasmine Baca , Joanne Xiu , Mehrie Patel , Benjamin Adam Weinberg , Emil Lou , Jashodeep Datta , Moh'd M. Khushman , Pat Gulhati , Sanjay Goel , Tiago Biachi de Castria , Vaia Florou , Kanika G. Nair , Suneel Deepak Kamath , Alok A. Khorana
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 536)
DOI
10.1200/JCO.2024.42.3_suppl.536
Abstract #
536
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.
First Author: Ian M. Silverman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Incidence and prognostic value of actionable mutations in early-stage resectable cholangiocarcinoma.
First Author: Kailey Morgan Oppat
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Peri-hilar cholangiocarcinoma (phCCA): A comparative comprehensive genomic profiling study.
First Author: Parth J Sampat
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle